메뉴 건너뛰기




Volumn 21, Issue 2, 2010, Pages 231-236

A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FOSTAMATINIB DISODIUM; IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; LIVER ENZYME; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE SYK INHIBITOR; R 788; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CCL2 PROTEIN, RAT; N4 (2,2 DIMETHYL 3 OXO 4H PYRID(1,4)OXAZIN 6 YL) 5 FLUORO N2 (3,4,5 TRIMETHOXYPHENYL) 2,4 PYRIMIDINEDIAMINE; N4-(2,2-DIMETHYL-3-OXO-4H-PYRID(1,4)OXAZIN-6-YL)-5-FLUORO-N2-(3,4,5-TRIMETHOXYPHENYL)-2,4-PYRIMIDINEDIAMINE; OXAZINE DERIVATIVE; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; R788 COMPOUND; SIGNAL PEPTIDE;

EID: 77949363952     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009030263     Document Type: Article
Times cited : (69)

References (26)
  • 2
    • 33750127369 scopus 로고    scopus 로고
    • Current pharmacotherapy for the treatment of crescentic glomerulonephritis
    • Tam FWK: Current pharmacotherapy for the treatment of crescentic glomerulonephritis. Expert Opin Investig Drugs 15: 1353-1369, 2006
    • (2006) Expert Opin Investig Drugs , vol.15 , pp. 1353-1369
    • Tam, F.W.K.1
  • 4
    • 0037407787 scopus 로고    scopus 로고
    • Both Fcgamma receptor i and Fcgamma receptor III mediate disease in accelerated nephrotoxic nephritis
    • Tarzi RM, Davies KA, Claassens JW, Verbeek JS, Walport MJ, Cook HT: Both Fcgamma receptor I and Fcgamma receptor III mediate disease in accelerated nephrotoxic nephritis. Am J Pathol 162: 1677-1683, 2003
    • (2003) Am J Pathol , vol.162 , pp. 1677-1683
    • Tarzi, R.M.1    Davies, K.A.2    Claassens, J.W.3    Verbeek, J.S.4    Walport, M.J.5    Cook, H.T.6
  • 7
    • 0032555744 scopus 로고    scopus 로고
    • Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide
    • Futterer K, Wong J, Grucza RA, Chan AC, Waksman G: Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide. J Mol Biol 281: 523-537, 1998
    • (1998) J Mol Biol , vol.281 , pp. 523-537
    • Futterer, K.1    Wong, J.2    Grucza, R.A.3    Chan, A.C.4    Waksman, G.5
  • 13
    • 34047205066 scopus 로고    scopus 로고
    • Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glo-merulonephritis and suppresses monocyte chemoattractant protein-1 but not IL-1beta or IL-6
    • Sheryanna A, Bhangal G, McDaid J, Smith J, Manning A, Foxwell BM, Feldmann M, Cook HT, Pusey CD, Tam FWK: Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glo-merulonephritis and suppresses monocyte chemoattractant protein-1 but not IL-1beta or IL-6. J Am Soc Nephrol 18: 1167-1179, 2007
    • (2007) J Am Soc Nephrol , vol.18 , pp. 1167-1179
    • Sheryanna, A.1    Bhangal, G.2    McDaid, J.3    Smith, J.4    Manning, A.5    Foxwell, B.M.6    Feldmann, M.7    Cook, H.T.8    Pusey, C.D.9    Tam, F.W.K.10
  • 15
    • 17744382183 scopus 로고    scopus 로고
    • Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis
    • Khan SB, Cook HT, Bhangal G, Smith J, Tam FW, Pusey CD: Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 67: 1812-1820, 2005
    • (2005) Kidney Int , vol.67 , pp. 1812-1820
    • Khan, S.B.1    Cook, H.T.2    Bhangal, G.3    Smith, J.4    Tam, F.W.5    Pusey, C.D.6
  • 17
    • 0033964770 scopus 로고    scopus 로고
    • Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis
    • Tam FWK, Smith J, Agarwal S, Karkar AM, Morel D, Thompson EM, Pusey CD: Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis. Nephron 84: 58-66, 2000
    • (2000) Nephron , vol.84 , pp. 58-66
    • Tam, F.W.K.1    Smith, J.2    Agarwal, S.3    Karkar, A.M.4    Morel, D.5    Thompson, E.M.6    Pusey, C.D.7
  • 18
    • 85058200770 scopus 로고    scopus 로고
    • Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glo-merular basement membrane glomerulone-phritis
    • Iyoda M, Shibata T, Kawaguchi M, Yamaoka T, Akizawa T: Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glo-merular basement membrane glomerulone-phritis. Kidney Int 75: 1060-1070, 2009
    • (2009) Kidney Int , vol.75 , pp. 1060-1070
    • Iyoda, M.1    Shibata, T.2    Kawaguchi, M.3    Yamaoka, T.4    Akizawa, T.5
  • 19
    • 43249129993 scopus 로고    scopus 로고
    • The kinase Syk as an adaptor controlling sustained calcium signalling and B-cell development
    • Kulathu Y, Hobeika E, Turchinovich G, Reth M: The kinase Syk as an adaptor controlling sustained calcium signalling and B-cell development. EMBO J 27: 1333-1344, 2008
    • (2008) EMBO J , vol.27 , pp. 1333-1344
    • Kulathu, Y.1    Hobeika, E.2    Turchinovich, G.3    Reth, M.4
  • 22
    • 24744449505 scopus 로고    scopus 로고
    • Syk is required for monocyte/macrophage chemotaxis to CX3CL1 (Fractalkine)
    • Gevrey JC, Isaac BM, Cox D: Syk is required for monocyte/macrophage chemotaxis to CX3CL1 (Fractalkine). J Immunol 175: 3737-3745, 2005
    • (2005) J Immunol , vol.175 , pp. 3737-3745
    • Gevrey, J.C.1    Isaac, B.M.2    Cox, D.3
  • 24
    • 0141991076 scopus 로고    scopus 로고
    • Monocyte chemoattractant protein (MCP)-1 production via functionally reconstituted Fcalpha receptor (CD89) on glomerular mesangial cells
    • Tsuge T, Suzuki Y, Shimokawa T, Horikoshi S, Okumura K, Ra C, Tomino Y: Monocyte chemoattractant protein (MCP)-1 production via functionally reconstituted Fcalpha receptor (CD89) on glomerular mesangial cells. Inflamm Res 52: 428-432, 2003
    • (2003) Inflamm Res , vol.52 , pp. 428-432
    • Tsuge, T.1    Suzuki, Y.2    Shimokawa, T.3    Horikoshi, S.4    Okumura, K.5    Ra, C.6    Tomino, Y.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.